$TEM (Tempus AI) — 8-K: Tempus inks BMS and Pathos data deals worth $192.5 million over five years

Tempus entered agreements with Bristol-Myers Squibb and Pathos AI providing aggregate cash payments of $192.5 million over approximately five years. The oncology Statement of Work with BMS covers $137.5 million in fixed quarterly payments through December 31, 2031, licensing de-identified oncology data and Lens software access. The neurology Order Form with Pathos provides up to $55 million, consisting of $50 million in data license fees at $100 per delivered record for 500,000 records over five years and $5.0 million for record updates. The deals expand use of Tempus's de-identified multimodal data and machine learning tools in therapeutic development.

Tempus entered agreements with Bristol-Myers Squibb and Pathos AI providing aggregate cash payments of $192.5 million over approximately five years. The oncology Statement of Work with BMS covers $137